Updates from ongoing, first-in-human phase 1 dose escalation and expansion study of TTI-621, a novel biologic targeting CD47, in patients with relapsed or refractory hematologic malignancies Meeting Abstract
| Authors: | Horwitz, S. M.; Foran, J. M.; Maris, M.; Sawas, A.; Okada, C.; Feldman, T. A.; Minden, M. D.; Sokol, L.; Mei, M.; Flinn, I. W.; Villa, D.; Percival, M. E. M.; Jagadeesh, D.; Savage, K. J.; Akilov, O. E.; Diefenbach, C.; Kim, Y. H.; Lin, G. H. Y.; Catalano, T.; Petrova, P. S.; Uger, B.; Molloy, N.; Large, K.; Shou, Y.; Ansell, S. M. |
| Abstract Title: | Updates from ongoing, first-in-human phase 1 dose escalation and expansion study of TTI-621, a novel biologic targeting CD47, in patients with relapsed or refractory hematologic malignancies |
| Meeting Title: | 62nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-05 |
| Language: | English |
| ACCESSION: | WOS:000607205605244 |
| DOI: | 10.1182/blood-2020-136198 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 41 -- Source: Wos |
